Clinical Research Directory
Browse clinical research sites, groups, and studies.
Omics of Rituximab-resistance
Sponsor: Mario Negri Institute for Pharmacological Research
Summary
The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict response to RTX, ultimately enabling optimized treatment selection. Using a multiomics approach, we will analyse genetic variants, serum and kidney proteomics, and serum metabolomics profiles from a well-characterised retrospective cohort of MN patients to uncover predictive biomarkers of RTX response. This is a non-pharmacological interventional study, conducted on biological samples from patients stored in the local biobank and on samples from healthy volunteers, which will be collected and subsequently stored in the biobank.
Official title: Identification of a Pharmacogenomic Signature for Anti-B Cell Precision Therapy in Membranous Nephropathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2026-04
Completion Date
2029-03
Last Updated
2026-02-18
Healthy Volunteers
Yes
Conditions
Interventions
Multi-omics Analysis
High-level molecular profiling (pharmacogenetics, proteomics, metabolomics, and scRNAseq) on patient samples
Sample collection
One single blood sample of approximately 25 ml.
Locations (1)
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, Italy